Posted by Michael Wonder on 27 Sep 2016
FDA approves Stelara (ustekinumab) for treatment of adults with moderately to severely active Crohn's disease
26 September 2016 - First biologic that targets interleukin-12 and interleukin-23 cytokines for the treatment of Crohn's disease.
Janssen announced today that the U.S. FDA has approved Stelara (ustekinumab) for the treatment of moderately to severely active Crohn's disease in adults (18 years or older) who have failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with a tumor necrosis factor blocker, or who failed or were intolerant to treatment with one or more TNF blockers.
Stelara is the first biologic therapy for Crohn's disease targeting interleukin (IL)-12 and IL-23 cytokines, which play a key role in inflammatory and immune responses.
